Drugs / IBI356
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06193434 | Jan 2024 → Aug 2025 | atopic eczema | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07330934 | Dec 2025 → Jun 2027 expected | atopic eczema | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI356 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06193434 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT07330934 ↗ |